SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) September 25, 2018
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
|(Commission File Number)||(IRS Employer Identification No.)|
|3950 South Country Club Road, Suite 470, Tucson, Arizona||85714|
|(Address of principal executive offices)||(Zip Code)|
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|o||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|o||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|o||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
|Item 5.02||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
On September 25, 2018, Joan Martin resigned from his position as Executive Vice President and Head of Europe, Middle East, and Africa of Accelerate Diagnostics, Inc. (the “Company”), effective immediately. Lawrence Mehren, President and Chief Executive Officer of the Company, will oversee operations of the region on an interim basis until the vacancy is filled.
On September 27, 2018, the Company issued a press release regarding Mr. Martin’s resignation. A copy of the press release is attached hereto as Exhibit 99.1.
|Item 9.01||Financial Statements and Exhibits.|
|(d)||Exhibits. The following materials are filed as exhibits to this Current Report on Form 8-K:|
|99.1||Press Release, dated September 27, 2018|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 27, 2018
ACCELERATE DIAGNOSTICS, INC.
/s/ Steve Reichling
Chief Financial Officer
|99.1||Press Release, dated September 27, 2018|
Accelerate Diagnostics announces resignation of Joan Martin as Head of Europe, Middle East, and Africa
TUCSON, Ariz., September 27, 2018 -- Accelerate Diagnostics, Inc. announced today that Joan Martin resigned from his position as Executive Vice President and Head of Europe, Middle East, and Africa and will be leaving the company for personal reasons.
“We thank Joan for his many contributions to Accelerate,” said Lawrence Mehren, President and CEO of Accelerate Diagnostics. “His leadership and guidance has enabled us to build a strong team and growing presence within these important multinational markets. We wish him the best in his future endeavors.”
Mr. Mehren will oversee operations of the region on an interim basis until the vacancy is filled.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results within 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100, firstname.lastname@example.org
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100, email@example.com
Source: Accelerate Diagnostics, Inc.